Seattle Genetics Inc(SGEN)stock report

Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company’s marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC). In addition to ADCETRIS, the Company’s pipeline includes other clinical-stage ADC programs, such as ASG-22ME, SGN-LIV1A, SGN-CD19A, SGN-CD19B, SGN-CD123A, SGN-352A, and ASG-15ME, as well as two immuno-oncology agents, SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology, and SGN-2FF, which is a small molecule. It also has multiple preclinical and research-stage programs that employ its technologies, including SGN-CD48A and a preclinical ADC. ADCETRIS is an ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent.

Q3 2019(9/30/19): Cash 870M. Loss 91.43M

EPS and Sales:

Date EPS % last year % last quarter
2018.12.31 -1.41 -60.23% 113.64%
2019.3.31 -0.08 89.04% 94.33%
2019.6.30 -0.57 -147.83% -41.00%
2019.9.30 -1.13 -71.21% -98.25%


Date Sales % last year % last quarter
2018.12.31 655M 35.76% 26.72%
2019.3.31 195M 38.84% -70.23%
2019.6.30 414M 33.11% 112.31%
2019.9.30 627M 30.56% 51.45%


Insider Transactions:

Institution Ownership:

Total institutions: 363,no change
Shares hold: 167000k shares. no change
shares% hold: 97.54%,no change

Analyst Ratings:

2019.12.19:Seattle Genetics shares are trading higher after the FDA granted accelerated approval to its PADCEV for the treatment of adult patients with locally advanced or metastatic urothelial cancer.(Benzinga)

Leave a Reply